Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):200-8

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

EXPERT OPINIONS   Freefree

Minerva Anestesiologica 2013 February;79(2):200-8

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Colistin in critically ill patients

Boisson M. 1, 2, Gregoire N. 1, Couet W. 1, 3, Mimoz O. 1, 2

1 Inserm U1070, Faculty of Medicine and Pharmacy, University of Poitiers, Poitiers, France; 2 Department of Anesthesiology and Intensive Care Unit, University Hospital of Poitiers, Poitiers, France; 3 Toxicology and Pharmacokinetic Unit, University Hospital of Poitiers, Poitiers, France


PDF


Colistin is a re-emerging old antibiotic that is used as a salvage treatment against multidrug-resistant Gram-negative infections. Because it is administrated as an inactive prodrug, colistin methanesulfonate (CMS) that undergoes rapid hydrolyze to colistin, pharmacokinetic studies using biological assays are unreliable. With the recent development of new assays using high performance liquid chromatography (HPLC) accurate pharmacokinetic of CMS and formed colistin is now available in various populations. This article aims to update previous reports on pharmacodynamics, pharmacokinetics, safety and clinical use of colistin, with a special focus on data useful to treat critically ill patients.

top of page